Please assess the completion status of the following clinical trial:

Trial Title: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for metastatic disease and without evidence of disease progression on treatment~* Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.~* Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious~* Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 weeks of continuous platinum treatment and have no evidence of progression based on investigator's opinion.~* Patients who have received platinum as potentially curative treatment for a prior cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and initiation of the platinum-based chemotherapy for metastatic pancreas cancer.~Major Exclusion Criteria:~* gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, Variants of uncertain clinical significance or Variant of unknown significance or Variant, favour polymorphism or benign polymorphism etc.)~* Progression of tumour between start of first line platinum based chemotherapy for metastatic pancreas cancer and randomisation.~* Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle~  1 Day 1 is not permitted.~* Exposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation~* Any previous treatment with a PARP inhibitor, including Olaparib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Olaparib (Type: EXPERIMENTAL): Olaparib tablets po. 300 mg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).